CLX — tear sheet

The engine's final decision rates CLX Underweight, judging the documented pressures real but not decisive enough for a full exit. Management's press release (8-K Item 2.02, 2026-08-03) shows Q4 FY26 net sales down 2% to $1.95 billion, organic sales down 13%, gross margin down 520 basis points to 41.3%, and adjusted EPS down 42% to $1.66, with the decline attributed to operating factors — lower net sales and gross margin — rather than one-time items. The engine isolates roughly 220 basis points of underlying margin erosion from volume, commodity, and manufacturing and logistics costs. Per the quantorb 13F dataset, comparable filers show a net disclosed reduction of about 256,674 shares, led by Nuance's 35.4% cut. The QuantOrb MFI 4.18 / BUY 0.7904 screen (2026-09-17) is an unconfirmed, single-session output that the engine says cuts both ways. Offsets include the 10-K franchise profile and the disclosed mechanical margin effects. Sources: SEC 8-K Item 2.02 press release (2026-08-03); QuantOrb money-flow snapshot (2026-09-17); SEC 13F-HR as of 2026-03-31 via quantorb filers data; SEC 10-K (filed 2026-08-07); engine final decision.

Source: SEC 13F-HR holdings (as of 2026-03-31) via quantorb filers data — quarter-end snapshots, statutory lag up to 45 days

Quarter-end 13F-HR snapshot for CLX as tracked in the quantorb filers dataset (5 institutional filer rows on file; positions as of 2026-03-31, a quarter-end snapshot subject to the statutory 13F reporting lag of up to 45 days). Quarter-over-quarter share changes where the dataset carries them:

This is the dataset's tracked top-holder snapshot, not an exhaustive list of 13F filers; it is a periodic regulatory disclosure, not real-time portfolio data.

Management's press release (8-K Item 2.02, 2026-08-03) carries the headline 'Delivers Q4 results in line with expectations while advancing strategic investments' and reports Q4 net sales down 2% to $1.95 billion, organic sales down 13% (about 13.5 points from lapping ERP-transition shipments), gross margin down 520 basis points to 41.3%, diluted EPS down 50% to $1.34, and adjusted EPS down 42% to $1.66. It announces the April 2026 completion of the GOJO Industries acquisition — now operating as Clorox Purell — which added about 10 points to quarterly net sales, and states a fiscal 2027 outlook was provided, though outlook figures are not available in provided documents. The 10-K (filed 2026-08-07) frames the franchise at $6.7 billion FY26 net sales across about 95 markets, with over 80% of sales from No. 1 or No. 2 brands. The engine lists FY27 outlook figures, the post-GOJO balance sheet, and June 30 13F flows as reassessment catalysts. Sources: management's press release (8-K Item 2.02, 2026-08-03); SEC 10-K (filed 2026-08-07); engine outputs.

The engine's risk review and the documents highlight several pressures. After roughly 300 basis points of disclosed mechanical margin effects — the ERP comparison and the GOJO inventory step-up, each about 150 basis points — about 220 basis points of gross-margin decline remains from lower volume, higher commodity costs, and higher manufacturing and logistics costs, which the press release says cost savings only 'partially offset.' GOJO's financing, leverage, and synergy economics are not available in provided documents, so the engine declines to underwrite the acquisition. The 13F snapshot (as of 2026-03-31, lag up to 45 days) is stale and partial, with three of five tracked filers lacking comparisons; the QuantOrb MFI 4.18 / BUY 0.7904 print is a single-session screen output the engine says cuts both ways. Price, OHLCV, macro, and news data are absent, and the review notes the ERP comp can contaminate FY27 comparisons as it did FY26. Sources: management's press release (8-K Item 2.02, 2026-08-03); SEC 13F-HR as of 2026-03-31 via quantorb filers data; QuantOrb money-flow snapshot (2026-09-17); engine risk review.